Information Provided By:
Fly News Breaks for May 1, 2018
KPTI, STML
May 1, 2018 | 07:23 EDT
Karyopharm Therapeutics' (KPTI) positive data last night for selinexor in multiple myeloma validates the mechanism of XPO1 inhibition, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. As such, the analyst is "cautiously optimistic" about the potential of Stemline Therapeutics' (STML) SL-801 for the treatment of cancers. SL-801 is an oral small molecule inhibitor of XPO1 and is being investigated in a Phase 1 trial in patients with advanced solid tumors, Selvaraju points out. He notes SL-801 is currently excluded in his $38 price target for Stemline. Selvaraju reiterates a Buy rating on the shares.
News For STML;KPTI From the Last 2 Days
There are no results for your query STML;KPTI